Instil Bio company information, Employees & Contact Information

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) Yahoo Finance

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

35% Treatment Response: Instil Bio's Novel Cancer Drug Shows Promise in Advanced Lung Cancer Patients Stock Titan

Instil Bio Names John Maraganore, Ph.D., To Board citybiz

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors Yahoo Finance

Frontline IMM2510 Plus Chemo Drives Responses in Advanced NSCLC OncLive

Instil Bio Appoints Jamie Freedman, M.D., Ph.D., as Chief Medical Officer citybiz

FDA Green Light: Instil Bio's Dual-Action Cancer Drug Advances to Clinical Trials for Hard-to-Treat Tumors Stock Titan

Instil Bio and ImmuneOnco to Host Investor and Analyst GlobeNewswire

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody Yahoo Finance

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site Yahoo Finance

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Antici GlobeNewswire

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China GlobeNewswire

Instil Bio Announces Clinical Progress in China for GlobeNewswire

Instil Bio and ImmuneOnco Announce Global Registrational GlobeNewswire

Instil Bio Stock Skyrockets 641% in One Week: Here's Why Yahoo Finance

Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer Dallas Innovates

Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) Seeking Alpha

Instil Bio: Chasing After Summit And BioNTech, Albeit With Some Hiccups Seeking Alpha

Instil Bio’s Strategic Shift To SYN-2510: A Speculative ‘Buy’ Opportunity (NASDAQ:TIL) Seeking Alpha

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? The Motley Fool

Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes Frontiers

Instil Bio announces closure of UK operations Investing.com

Instil Bio’s upsized IPO raises $320M for clinical tests of TIL cancer cell therapy MedCity News

TIL Stock Price and Chart — NASDAQ:TIL TradingView